| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.alembiclimited.com | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 3,022.32 Cr. | |
| Earnings per share (EPS) | 13.35 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | 8.82 | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 32.75 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 89.45 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 1.32 | Calculated using Price: 117.70 |
| Dividend Yield | 0.17 | Period Ending 2021-03 |
| No. of Shares Subscribed | 25.68 Cr. | 256,781,828 Shares |
| FaceValue | 2 | |
| Company Profile | ||
|
Alembic was incorporated in 1907 as Alembic Chemical Works Company, primarily engaged in production of tinctures and alcohol at Baroda. Later the company set up distillery plant for pharmaceutical purposes at Baroda. It started manufacturing of cough syrup, vitamins, tonics and sulphur drugs. In 1952, the company set up its research and development activity. Currently the company has developed research activity in area of chemistry, microbiology, pharmaceutical technology and bio-equivalence. The company’s manufacturing units are located in Baroda and Baddi. Company’s plant has received various certifications such as ISO-9002, ISO-14001 and ISO 27001 and also follows WHO-GMP guidelines. The company has presence in 75 countries globally. Business area APIs- The Company is engaged in manufacturing of active pharmaceutical ingredients for anti-parkinsons, anti-depressants, cephalosporins, macrolides and others. Bulk Pharmaceuticals- Under this the company manufactures bulk drugs that are phosgene based and intermediates. Formulation- The company manufactures around 150 products under this segment in therapeutic areas such as anti-infective, cough and cold products to cardiovascular and oral anti-diabetics. Herbal and Nutraceuticals- The company manufactures herbal and Nutraceuticals and has created brands like Isovon, Protinules, ALA-100, Diax and many more. Alembic also provides contract research services in area of chemistry, bioequivalence and bioanalytical. It also manufactures products for animal care such as Antibiotics-injections, Analgesics, Antipyretics, antidiarrhoeals, Vitamins-Oral and injectable, Tonics and Nutritional feed supplements. Outlook The company has acquired API manufacturing unit of Nirayu that is located at Gujarat at a consideration of Rs 17.50 Crores. |
||
Company Profile
Alembic was incorporated in 1907 as Alembic Chemical Works Company, primarily engaged in production of tinctures and alcohol at Baroda. Later the company set up distillery plant for pharmaceutical purposes at Baroda. It started manufacturing of cough syrup, vitamins, tonics and sulphur drugs.
In 1952, the company set up its research and development activity. Currently the company has developed research activity in area of chemistry, microbiology, pharmaceutical technology and bio-equivalence.
The company’s manufacturing units are located in Baroda and Baddi. Company’s plant has received various certifications such as ISO-9002, ISO-14001 and ISO 27001 and also follows WHO-GMP guidelines.
The company has presence in 75 countries globally.
Business area
APIs- The Company is engaged in manufacturing of active pharmaceutical ingredients for anti-parkinsons, anti-depressants, cephalosporins, macrolides and others.
Bulk Pharmaceuticals- Under this the company manufactures bulk drugs that are phosgene based and intermediates.
Formulation- The company manufactures around 150 products under this segment in therapeutic areas such as anti-infective, cough and cold products to cardiovascular and oral anti-diabetics.
Herbal and Nutraceuticals- The company manufactures herbal and Nutraceuticals and has created brands like Isovon, Protinules, ALA-100, Diax and many more.
Alembic also provides contract research services in area of chemistry, bioequivalence and bioanalytical. It also manufactures products for animal care such as Antibiotics-injections, Analgesics, Antipyretics, antidiarrhoeals, Vitamins-Oral and injectable, Tonics and Nutritional feed supplements.
Outlook
The company has acquired API manufacturing unit of Nirayu that is located at Gujarat at a consideration of Rs 17.50 Crores.
| 1 Day |
|
-2.89% |
| 1 Week |
|
-4.07% |
| 1 Month |
|
-8.12% |
| 3 Month |
|
-9.53% |
| 6 Month |
|
+19.01% |
| 1 Year |
|
+32.77% |
| 2 Year |
|
+176.94% |
| 5 Year |
|
+209.74% |
| 9 years | 2009-03 | 2010-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 3.22 | 11.83 | 5.58 | 3.71 | 3.21 | 4.18 | 3.58 | 7.08 | 0.75 | |
| Return on Capital Employed (%) | 7.79 | 10.54 | 3.82 | 3.82 | 3.12 | 4.44 | 3.91 | 7.12 | 0.94 | |
| Return on Assets (%) | 1.08 | 3.82 | 2.88 | 3.25 | 2.94 | 3.88 | 3.39 | 6.80 | 0.71 |
| Particulars | 7 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Shh. Funds | 528 | 803 | 911 | 1,086 | 1,209 | 1,418 | 2,297 | |
| Non Curr. Liab. | 38 | 15 | 13 | 14 | 9 | 7 | 53 | |
| Curr. Liab. | 82 | 58 | 68 | 59 | 49 | 46 | 59 | |
| Minority Int. | ||||||||
| Equity & Liab. | 648 | 876 | 992 | 1,159 | 1,266 | 1,471 | 2,409 | |
| Non Curr. Assets | 458 | 706 | 801 | 972 | 1,167 | 1,308 | 2,307 | |
| Curr. Assets | 189 | 169 | 191 | 187 | 99 | 163 | 102 | |
| Misc. Exp. not W/O | ||||||||
| Total Assets | 648 | 876 | 992 | 1,159 | 1,266 | 1,471 | 2,409 |
| Particulars | 7 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Net Sales | 144 | 128 | 147 | 125 | 124 | 74 | 74 | |
| Other Income | 22 | 29 | 31 | 37 | 29 | 94 | 11 | |
| Total Income | 166 | 156 | 178 | 162 | 153 | 167 | 84 | |
| Total Expenditure | -135 | -122 | -140 | -114 | -106 | -71 | -63 | |
| PBIDT | 30 | 35 | 38 | 48 | 48 | 97 | 21 | |
| Interest | -1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | -6 | -6 | -5 | -4 | -3 | -3 | -4 | |
| Taxation | 1 | -1 | 1 | -2 | -4 | 0 | -3 | |
| Exceptional Items | -3 | -6 | ||||||
| PAT | 24 | 25 | 27 | 42 | 41 | 93 | 14 |
| Particulars | 7 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 22 | 10 | 52 | 24 | 22 | 7 | -2 | |
| Cash Fr. Inv. | 5 | -5 | -47 | -22 | 72 | 57 | -35 | |
| Cash Fr. Finan. | -25 | -5 | -5 | -3 | -92 | -6 | -15 | |
| Net Change | 2 | 0 | 0 | -1 | 1 | 57 | -52 | |
| Cash & Cash Eqvt | 3 | 2 | 2 | 1 | 2 | 59 | 7 |
|
Tue, 03 Aug 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform the exchange that the following share certificate(s) of the Company has been reported as lost/misplaced and the shareholder of such lost share certificate(s) has requested the Company for issue of duplicate share certificate(s): Also find attached herewith copy of email received from RTA as a proof of date of receipt of information by the Company. We request you to kindly take the same on record. |
|
Wed, 28 Jul 2021
Board Meeting Intimation for Board Meeting To Consider Unaudited Financial Results For The Quarter Ended 30Th June 2021 ALEMBIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2021 inter alia to consider and approve With reference to the captioned matter the Exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Friday 6th August 2021 inter alia to consider and approve Unaudited Financial Results of the Company for the quarter ended 30th June 2021. Pursuant to the Companys Code of Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives the trading window for dealing in securities of the Company which was closed from 1st July 2021 will reopen 48 hours after the declaration of the financial results. We request you to kindly take the same on record. |
|
Mon, 19 Jul 2021
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform the exchange that the following share certificate(s) of the Company has been reported as lost/misplaced and the shareholder of such lost share certificate(s) have requested the Company for issue of duplicate share certificate(s): Also find attached herewith copy of email received from RTA as a proof of date of receipt of information by the Company. We request you to kindly take the same on record. |
| Thu, 05 Aug 2021 |
Higher Delivery Quantity
|
Close Crossing Last Week Low
|
Close Crossing Last Month Low
|
Close Crossing Last Month Close from Above
|
Opening at High
|
Equities
M.F.
Sectors